Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 16/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 16/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 16/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 16/20 | 0.55 |
| ▸ | DYRK3 | O43781 | 15/20 | 0.55 |
| ▸ | DYRK2 | Q92630 | 15/20 | 0.55 |
| ▸ | CLK2 | P49760 | 14/20 | 0.55 |
| ▸ | CLK3 | P49761 | 9/20 | 0.55 |
| ▸ | DYRK4 | Q9NR20 | 7/20 | 0.43 |
| ▸ | GSK3B | P49841 | 5/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25212107 | 1.00 | CLK1 (0.55) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL30144887 | 1.00 | CLK1 (0.55) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL30144911 | 1.00 | CLK1 (0.55) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL30494160 | 0.82 | CLK1 (0.54) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL23970214 | 0.82 | CLK1 (0.64) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL30494174 | 0.82 | CLK1 (0.54) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL23970258 | 0.82 | CLK1 (0.64) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL23970231 | 0.82 | CLK1 (0.64) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL26103452 | 0.82 | CLK1 (0.54) | CLK1CLK4DYRK1ADYRK1BDYRK3 | |
| SCHEMBL26103457 | 0.82 | CLK1 (0.54) | CLK1CLK4DYRK1ADYRK1BDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143185-B1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-10-29 | — | — | EP | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | claimed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | claimed |
| EP-4143185-B1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-12398129-B2 | Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-08-26 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398129-B2 | Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 | CLK1, CLK2, CLK4 | CLK1 1/4885CLK4 3/4885DYRK1A 19/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | CLK1 1/4885CLK4 4/4885DYRK1A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.